Bevacizumab and Carboplatin for Patients With Ovarian Cancer

Exclusion Criteria

• •1. Patients who have received other types of experimental treatment or participated in a clinical study less than 28 days prior to this study.
• •2. Pregnant or breastfeeding women. A negative pregnancy test is mandatory for fertile women.
• •3. Fertile women, who do not wish to use safe contraception (e.g., birth control pills, coil, gestagen deposit injection, subdermal implantation, hormonal vagina ring, and transdermal deposit band-aid).
• •4. Untreated bowel obstruction or massive gastrointestinal tumors verified by CT scan.
• •5. Other present or previous malignant disease apart from curatively treated non-melanoma skin cancer or other types of cancer with minimal risk of relapse.
• •6. CNS-metastases.
• •7. Underlying medical disease not adequately treated (diabetes, cardiovascular disease).
• •8. Uncontrolled hypertension (persistent BP \> 150/100 despite antihypertensive treatment).
• •9. Surgery incl. open biopsy less than 4 weeks before expected first dose of Bevacizumab.
• •10. Patients with non-healing wounds or fractures.
• •11. Previous cerebrovascular attack (TVA), transient ischaemic attack (TIA) or subarachnoidal bleeding (SAH) within last six months.
• •12. Thromboembolic or haemorrhagic disease in the anamnesis.
• •13. Clinically significant cardiovascular disease including Myocardial infarction or unstable angina less than 6 months prior to treatment
• •* New York heart Association NYHA class ≥ 2
• •* Poorly controlled cardial arrythmia despite medical treatment
• •* Peripheral vascular disease, grade 3 or above.
• •14. Present or previous chronical use of Aspirin (less than 10 days before start of treatment) Aspirin \> 325 mg daily.
• •15. Present or recent use of full dose oral or parenteral anticoagulant or thrombolytic medicine.
• •16. Preexisting neuropathy, sensoric or motoric ≥ grade 2.
• •17. Decreased hearing.
• •18. Bleeding tumor.
• •19. Hypersensitivity to the active substance or one or more of the other substances contained in the protocol drugs.
• •20. Hypersensitivity to products from ovarian cells (CHO) from Chinese hamster or other recombinant or humanized antibodies.